The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: JD Sports falls after Nike cuts revenue forecast

Fri, 24th Sep 2021 09:02

(Alliance News) - Stock prices in London opened lower on Friday amid growing worries over the UK's economic prospects, while JD Sports fell to the bottom of the FTSE 100 after top brand Nike warned that supply issues will hurt annual revenue.

The FTSE 100 index was down 22.46 points, or 0.3%, at 7,055.89 early Friday. The mid-cap FTSE 250 index was down 94.85 points, or 0.4%, at 23,735.85. The AIM All-Share index was flat at 1,271.98.

The Cboe UK 100 index was down 0.3% at 701.40. The Cboe 250 was down 0.3%, at 21,524.30. The Cboe Small Companies was 0.1% lower at 15,592.80.

In mainland Europe, the CAC 40 stock index in Paris was down 0.5% and the DAX 40 index in Frankfurt was down 0.7%.

Consumer confidence in the UK has plunged amid increasing anxiety about the rising cost of living, a long-running survey suggested.

GfK's Consumer Confidence Barometer fell by five points to minus 13 in September, a drop not seen since October last year. All measures of the survey, including confidence in the general economic situation and personal finances, were down in comparison to last month.

"When consumer confidence drops, shoppers tend to spend less, and this dampens the overall economic prospects for the UK. This really is an unwelcome picture going into 2022 and beyond," said GfK's Joe Staton.

The index also recorded a three-point drop to minus six in the major purchase index, an indicator of consumer confidence in buying big ticket items, in worrying news for hard-pressed retailers looking to build sales as they go into the key holiday period.

"Rising inflation, cuts to government support schemes, the power crisis along with the potential lack of products available are clearly a worry within the UK and likely to be causing big challenges for the Conservative party, especially with its upcoming annual conference. We expect these concerns to remain headwinds to the GfK consumer index recovery, throughout the upcoming months," said analysts at Shore Capital.

In the FTSE 100, AstraZeneca was the best performer, up 3.3%, after the drugmaker announced positive results from the PROpel phase three trial of Lynparza.

The Anglo-Swedish firm said that the PROpel phase three trial for Lynparza achieved its primary endpoint of radiographic progression-free survival in men with metastatic castration-resistant prostate cancer, compared to standard-of-care abiraterone.

Interim analysis by the Independent Data Monitoring Committee concluded that the trial met the primary endpoint in men which had not received treatment in the first-line setting including new hormonal agents or chemotherapy.

At the other end of the large-caps, JD Sports Fashion was the worst performer, down 2.7%, with the sportswear retailer suffering a negative read-across from Nike.

The US athletic apparel maker late Thursday reopened first quarter results which missed consensus estimates. The stock fell 3.9% in after-hours trade in New York.

In the period ended August 31, Nike's revenue climbed 16% annually to USD12.25 billion from USD10.59 billion a year earlier. Quarter-on-quarter, revenue declined 0.8%. The first-quarter top line came in below CNN-cited consensus of USD12.5 billion.

On the subsequent conference call, Nike said sales may fall as factory closures in Vietnam prevent the company from keeping up with consumer demand.

"Several of our factory partners in Vietnam and Indonesia were required to abruptly cease operations in the first quarter. As of today, Indonesia is now fully operational, but in Vietnam, nearly all footwear factories remain closed by government mandate. Our experience with COVID-related factory closures suggest that re-opening and ramping back to full production scale takes time," Nike said.

As such, Nike said full-year revenue will be in the mid-single-digits rather than a low double-digit percentage rate it earlier targeted.

"The problem for Nike is that these problems are not easy to fix and there is no telling when the situation will improve. The CEO of Covid vaccine maker Moderna predicted yesterday that it would take another year for the pandemic to disappear, meaning the current supply bottleneck could last for months," said eToro analyst Mark Crouch.

German sportswear brand Adidas was down 3.3% in Frankfurt.

In the FTSE 250, Mitie Group was up 3.0% after the outsourcer raised its profit guidance due to a series of Covid-linked contract awards.

Mitie said it now expects to deliver operating profit of between GBP145 million and GBP155 million in its financial year ending March 31, 2022. Operating profit before items was GBP63.4 million in financial 2021 and GBP86.1 million in financial 2020.

LondonMetric Property was up 2.0% after Citigroup raised the distribution and long income property investor to Buy from Hold.

The Japanese Nikkei 225 index closed up 2.1% on Friday, reopening after being closed for a holiday on Thursday. In China, the Shanghai Composite closed down 0.8%, while the Hang Seng index in Hong Kong was down 0.1%. The S&P/ASX 200 in Sydney ended down 0.4%.

The pound was quoted at USD.3705 early Friday, down from USD1.3736 at the London equity market close on Thursday.

The euro was priced at USD1.1732, little changed from USD1.1735. Against the Japanese yen, the dollar was trading at JPY110.44, up from JPY110.18.

Brent was quoted at USD77.61 a barrel Friday morning, up sharply from USD75.94 late Thursday. Gold stood at USD1,755.47 an ounce, higher against USD1,748.28.

Friday's economic calendar has Ifo's business climate index for Germany at 0900 BST.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.